

Savino Sciascia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787364/publications.pdf>

Version: 2024-02-01

269
papers

6,955
citations

61857

43
h-index

91712

69
g-index

273
all docs

273
docs citations

273
times ranked

6491
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
2	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	0.9	26
3	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. <i>Rheumatology</i> , 2022, 61, 1928-1935.	0.9	15
4	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
5	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial” comment on: “Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus” by Chatzidionysiou¹et al¹. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e140-e140.	0.5	9
6	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 9-21.	3.5	21
7	Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2022, 21, 103030.	2.5	5
8	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128
9	Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab. <i>Frontiers in Medicine</i> , 2022, 9, 819320.	1.2	4
10	Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease. <i>Nephron</i> , 2022, 146, 481-488.	0.9	4
11	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 575-580.	0.4	5
12	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	1.8	0
13	Dietary Patterns at the Individual Level through a Nutritional and Environmental Approach: The Case Study of a School Canteen. <i>Foods</i> , 2022, 11, 1008.	1.9	2
14	New Onset Biopsy-Proven Nephropathies after COVID Vaccination. <i>American Journal of Nephrology</i> , 2022, 53, 325-330.	1.4	32
15	Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 777134.	2.2	4
16	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5379.	1.2	2
17	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , 2022, 10, 663.	2.1	10
18	Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 2977.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Histological Kidney Re-Evaluation after Daratumumab Monotherapy for AL Amyloidosis. <i>Hemato</i> , 2022, 3, 367-372.	0.2	0
20	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€™Registryâ€™™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	1.1	9
21	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.5	9
22	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	1.5	60
23	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1804-1808.	1.5	7
24	Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. <i>Journal of Nephrology</i> , 2021, 34, 231-240.	0.9	2
25	Treatment of antiphospholipid syndrome. , 2021, , 621-628.		0
26	Efficacy of low or standard rituximab-based protocols and comparison to Ponticelliâ€™™s regimen in membranous nephropathy. <i>Journal of Nephrology</i> , 2021, 34, 565-571.	0.9	18
27	EULAR recommendations for a core data set for pregnancy registries in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 49-56.	0.5	36
28	Health Disparities in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 119-132.	0.8	7
29	Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players?. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13441.	1.7	6
30	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
31	Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. <i>Rheumatology</i> , 2021, 60, 1106-1113.	0.9	18
32	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. , 2021, , 109-134.		0
33	The effect of hydroxychloroquine on platelet activation in model experiments. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 674-679.	1.0	3
34	Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. <i>Journal of Oral Science</i> , 2021, 63, 217-226.	0.7	13
35	Antibodies as risk factors for adverse maternal and foetal outcomes. , 2021, , 56-64.		0
36	Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. <i>Rheumatology and Therapy</i> , 2021, 8, 81-94.	1.1	11

#	ARTICLE	IF	CITATIONS
37	A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. <i>Journal of Clinical Medicine</i> , 2021, 10, 292.	1.0	5
38	Antiphospholipidic Antibodies in SARS-CoV2 Infection: Still a Lot to Learn. <i>Medicina Interna (Bucharest, Romania: 1991)</i> , 2021, 18, 7-9.	0.1	0
39	Incidence of a First Thrombo-Embolitic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. <i>Frontiers in Medicine</i> , 2021, 8, 621590.	1.2	1
40	Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. <i>Lupus</i> , 2021, 30, 884-892.	0.8	3
41	Community Garden Initiatives Addressing Health and Well-Being Outcomes: A Systematic Review of Infodemiology Aspects, Outcomes, and Target Populations. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1943.	1.2	23
42	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 395-406.	1.3	6
43	Antiphospholipid syndrome: the need for new international classification criteria. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 385-394.	1.3	6
44	Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. <i>Minerva Medica</i> , 2021, 112, 162-174.	0.3	12
45	A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. <i>Kidney International Reports</i> , 2021, 6, 1081-1087.	0.4	12
46	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
47	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	2.1	9
48	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.	0.8	9
49	POS0172â€“...THROMBIN GENERATION ASSAY AND LUPUS ANTICOAGULANT IDENTIFY DIFFERENT POPULATIONS OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 298.1-299.	0.5	1
50	Antiphospholipid Antibodies and Infection: Non Nova Sed Nove. <i>Frontiers in Immunology</i> , 2021, 12, 687534.	2.2	14
51	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e447-e459.	2.2	36
52	Antiphospholipid antibodies and cerebrovascular thrombosis in the pediatric population: Few answers to many questions. <i>Lupus</i> , 2021, 30, 1365-1377.	0.8	0
53	Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 280.	1.2	8
54	Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology. <i>Thrombosis Research</i> , 2021, 202, 100-103.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. <i>Immunologic Research</i> , 2021, 69, 372-377.	1.3	4
56	A new challenge for lupus nephritis management: Induction therapy without immunosuppressive maintenance regimen. <i>Autoimmunity Reviews</i> , 2021, 20, 102844.	2.5	5
57	A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome. <i>Kidney International</i> , 2021, 100, 740-742.	2.6	4
58	Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). <i>European Journal of Internal Medicine</i> , 2021, 92, 134-136.	1.0	7
59	Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. <i>American Journal of Nephrology</i> , 2021, 52, 559-571.	1.4	15
60	Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. <i>Lancet Rheumatology</i> , The, 2021, 3, e832.	2.2	13
61	Moving toward personalized approaches in the management of lupus nephritis. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1547-1550.	1.4	1
62	Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. <i>Frontiers in Immunology</i> , 2021, 12, 769785.	2.2	6
63	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021, 61, 64.	0.8	0
64	The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. <i>Reumatismo</i> , 2021, 73, .	0.4	2
65	Quality of life measures in Systemic Lupus Erythematosus: A systematic review. <i>Reumatismo</i> , 2021, 73, .	0.4	2
66	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 938-946.	0.4	1
67	The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1071-1076.	0.4	2
68	An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 125-128.	0.4	3
69	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	1
70	An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 125-128.	0.4	11
71	The Challenging Management of Cancer: An Immunonephrologist's Perspective. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 114-120.	0.9	2
72	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. <i>Autoimmunity Reviews</i> , 2020, 19, 102449.	2.5	10

#	ARTICLE	IF	CITATIONS
73	P1251THROMBIN GENERATION ASSAY: A POTENTIAL TOOL TO STRATIFY THROMBOTIC RISK IN HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
74	Treatment of antiphospholipid syndrome. <i>Clinical Immunology</i> , 2020, 221, 108597.	1.4	11
75	Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. <i>Thrombosis Research</i> , 2020, 196, 432-434.	0.8	20
76	Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 784-791.	0.9	3
77	Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102622.	2.5	0
78	Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience. <i>Journal of Nephrology</i> , 2020, 34, 1767-1781.	0.9	11
79	Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement. <i>Immunologic Research</i> , 2020, 68, 340-352.	1.3	9
80	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28
81	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2020, 19, 102641.	2.5	13
82	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	2.2	3
83	Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3232.	1.0	7
84	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	0.8	27
85	Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. <i>Italian Journal of Pediatrics</i> , 2020, 46, 130.	1.0	14
86	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2921-2928.	1.9	7
87	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9551.	1.8	11
88	Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies. <i>Biomedicines</i> , 2020, 8, 622.	1.4	6
89	P0206RITUXIMAB IN ADULT ONSET OF IGA VASCULITIS WITH SEVERE RENAL INVOLVEMENT: A SINGLE CENTER EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
90	P0244OVERTURNING THE CONVENTIONAL PYRAMID OF AL AMYLOIDOSIS MANAGEMENT: DARATUMUMAB ADMINISTERED AS MONOTHERAPY IN SEVERE PATIENTS WITH BIOPSY PROVEN RENAL INVOLVEMENT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp – A Usability Study. International Journal of Environmental Research and Public Health, 2020, 17, 3469.	1.2	5
92	Hydroxychloroquine reduces IL-6 and pro-thrombotic status. Autoimmunity Reviews, 2020, 19, 102555.	2.5	7
93	CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. International Journal of Molecular Sciences, 2020, 21, 4129.	1.8	20
94	Antiphospholipid Syndrome Is Still a Rare Disease – Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte – Garcia et al. Arthritis and Rheumatology, 2020, 72, 1774-1776.	2.9	12
95	Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Internal and Emergency Medicine, 2020, 15, 861-863.	1.0	76
96	Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome. Thrombosis and Haemostasis, 2020, 120, 592-598.	1.8	41
97	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. Autoimmunity Reviews, 2020, 19, 102488.	2.5	5
98	Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global Antiphospholipid Syndrome Score. Seminars in Arthritis and Rheumatism, 2020, 50, 553-556.	1.6	13
99	Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. Journal of Nephrology, 2020, 33, 757-762.	0.9	6
100	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. Rheumatology, 2020, 59, 2412-2418.	0.9	19
101	Filling the gap in antiphospholipid syndrome diagnosis: a patient’s story. Lupus, 2020, 29, 236-238.	0.8	4
102	Value of colchicine as treatment for recurrent oral ulcers: A systematic review. Journal of Oral Pathology and Medicine, 2020, 49, 731-740.	1.4	17
103	Global antiphospholipid syndrome score and anti-β2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. Lupus, 2020, 29, 676-685.	0.8	13
104	OP0148 – MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 94-95.	0.5	3
105	Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review. European Journal of Rheumatology, 2020, 7, 31-34.	1.3	14
106	FRI0589 – CLINICAL ACCURACY OF ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN AND ANTI-BETA2GLYCOPROTEIN I DOMAIN I FOR PREDICTING CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME. Annals of the Rheumatic Diseases, 2020, 79, 899.1-900.	0.5	0
107	AB0409 – APL PREVALENCE IN WOMEN WITH LATE PREGNANCY COMPLICATION AND LOW-RISK FOR CHROMOSOMAL ABNORMALITIES. Annals of the Rheumatic Diseases, 2020, 79, 1504.1-1505.	0.5	0
108	Antiphospholipid Antibodies and Fertility: No Impact on Ovarian Reserve in Premenopausal Women. Journal of Clinical Rheumatology and Immunology, 2020, 20, 4-8.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 529-532.	0.4	196
110	Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 195-200.	0.4	3
111	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (<scp>APS</scp>) in the <scp>APS</scp> Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 656-661.	1.1	29
112	The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience. <i>European Journal of Internal Medicine</i> , 2019, 68, e12-e14.	1.0	1
113	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
114	Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6308-6318.	1.6	15
115	FP110 THE CYCLOPHOSPHAMIDE-SPARING EFFECT OF AN INTENSIFIED B-CELLS DEPLETION PROTOCOL IN ANCA-ASSOCIATED VASCULITIS: A CASE-CONTROL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
116	FP239 EFFICACY OF LOW OR STANDARD DOSE RITUXIMAB AS COMPARED TO PONTICELLIâ€™S REGIMEN IN MEMBRANOUS NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
117	IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. <i>Frontiers in Medicine</i> , 2019, 6, 211.	1.2	5
118	SP143 PERCUTANEOUS NATIVE RENAL BIOPSY AS A SAFE PROCEDURE IN OUTPATIENT WITH SYSTEMIC AUTOIMMUNE DISEASES: A MONOCENTRIC COHORT. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
119	Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1920-1926.	1.8	13
120	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
121	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008.	0.9	10
122	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
123	Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. <i>Rheumatology</i> , 2019, 58, 1870-1872.	0.9	1
124	Long-term evaluation of pemphigus vulgaris: A retrospective consideration of 98 patients treated in an oral medicine unit in north-west Italy. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 406-412.	1.4	15
125	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	2.2	34
126	THU0602â€™...THE ROLE OF INFRARED THERMOGRAPHY IN THE ASSESSMENT OF PERIPHERAL VASCULOPATHY AND IN THE THERAPEUTIC MANAGEMENT OF SYSTEMIC SCLEROSIS PATIENTS TREATED WITH SYNTHETIC PROSTANOIDS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	Acute kidney injury associated with glomerular diseases. <i>Current Opinion in Critical Care</i> , 2019, 25, 573-579.	1.6	11
128	The dilemma of treating hepatitis C virus-associated cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2019, 31, 499-504.	2.0	5
129	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1004-1006.	0.5	23
130	Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 741-744.	1.6	12
131	Nailfold Capillaroscopy Patterns. <i>Israel Medical Association Journal</i> , 2019, 21, 497-498.	0.1	0
132	Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic". <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961875834.	0.3	2
133	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	1.8	62
134	Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. <i>Rheumatology</i> , 2018, 57, 661-665.	0.9	49
135	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	1.6	42
136	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	18.1	233
137	Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. <i>Lupus</i> , 2018, 27, 1393-1394.	0.8	7
138	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	1.7	30
139	The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. <i>European Journal of Neurology</i> , 2018, 25, 320-325.	1.7	24
140	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , 2018, 27, 399-406.	0.8	51
141	Prevalence and Thrombotic Risk Assessment of Anti-Î²2 Glycoprotein I Domain I Antibodies: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 466-474.	1.5	60
142	Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223302.	0.2	1
143	Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. <i>Oncotarget</i> , 2018, 9, 28799-28804.	0.8	23
144	Thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 21-27.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?. Expert Review of Clinical Immunology, 2018, 14, 877-879.	1.3	5
146	Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Annals of the Rheumatic Diseases, 2018, 77, 1694-1695.	0.5	28
147	Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients. Thrombosis Research, 2018, 170, 28-31.	0.8	1
148	Recent advances in the management of systemic lupus erythematosus. F1000Research, 2018, 7, 970.	0.8	23
149	Multifocal avascular osteonecrosis despite appropriate anticoagulation therapy in a patient with systemic lupus erythematosus and antiphospholipid syndrome. BMJ Case Reports, 2018, 2018, bcr-2018-225532.	0.2	5
150	Thymic stromal lymphopoietin in human pancreatic ductal adenocarcinoma: expression and prognostic significance. Oncotarget, 2018, 9, 32795-32809.	0.8	3
151	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. European Journal of Rheumatology, 2018, 5, 92-95.	1.3	14
152	Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Internal and Emergency Medicine, 2017, 12, 1-7.	1.0	28
153	Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. Autoimmunity Reviews, 2017, 16, 287-293.	2.5	60
154	Global Antiphospholipid Syndrome Score. Handbook of Systemic Autoimmune Diseases, 2017, 12, 215-219.	0.1	0
155	Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review. Autoimmunity Reviews, 2017, 16, 469-477.	2.5	34
156	Lupus nephritis and pregnancy outcome. Autoimmunity Reviews, 2017, 16, 433-434.	2.5	8
157	Infodemiology of systemic lupus erythematosus using Google Trends. Lupus, 2017, 26, 886-889.	0.8	32
158	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatology International, 2017, 37, 1249-1255.	1.5	61
159	Antiphospholipid antibodies: crossroads between autoimmunity and infections?. Internal and Emergency Medicine, 2017, 12, 557-558.	1.0	0
160	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Seminars in Thrombosis and Hemostasis, 2017, 43, 562-571.	1.5	89
161	The adjusted Global Antiphospholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. International Journal of Cardiology, 2017, 240, 72-77.	0.8	48
162	Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials. Clinical Drug Investigation, 2017, 37, 519-524.	1.1	30

#	ARTICLE	IF	CITATIONS
163	Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. <i>BioDrugs</i> , 2017, 31, 37-49.	2.2	30
164	What can Google and Wikipedia can tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus. <i>International Journal of Medical Informatics</i> , 2017, 107, 65-69.	1.6	25
165	Current insights in obstetric antiphospholipid syndrome. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 397-403.	0.9	41
166	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	2.5	19
167	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <i>Internal and Emergency Medicine</i> , 2017, 12, 1101-1108.	1.0	14
168	Hydroxychloroquine and the eye: an old unsolved problem. <i>Eye</i> , 2017, 31, 1744-1744.	1.1	2
169	High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. <i>American Journal of Nephrology</i> , 2017, 46, 108-113.	1.4	24
170	The Cutaneous Spectrum of Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 291-305.	2.9	83
171	Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. <i>Nature Reviews Rheumatology</i> , 2017, 13, 548-560.	3.5	153
172	How I treat patients with systemic sclerosis in clinical practice. <i>Autoimmunity Reviews</i> , 2017, 16, 1024-1028.	2.5	20
173	Immunological Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 497-509.	0.8	2
174	Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. <i>BMJ Open</i> , 2017, 7, e015243.	0.8	26
175	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1923-1932.	1.1	60
176	Radiotherapy in patients with HIV: current issues and review of the literature. <i>Lancet Oncology</i> , The, 2017, 18, e379-e393.	5.1	15
177	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.5	1
178	AB1014...Safety of outpatient percutaneous native renal biopsy in patients with systemic autoimmune diseases: results from a monocentric cohort. , 2017, , .		0
179	The 4 plus 2 rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. <i>Oncotarget</i> , 2017, 8, 52072-52077.	0.8	15
180	The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. <i>Oncotarget</i> , 2017, 8, 41764-41777.	0.8	28

#	ARTICLE	IF	CITATIONS
181	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
182	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Thrombosis and Haemostasis, 2016, 115, 285-290.	1.8	66
183	Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. American Journal of Nephrology, 2016, 43, 251-260.	1.4	38
184	Antiphospholipid syndrome. Best Practice and Research in Clinical Rheumatology, 2016, 30, 133-148.	1.4	48
185	Autoantibodies and Biomarkers: Diagnostic Aspects. Rare Diseases of the Immune System, 2016, , 47-59.	0.1	0
186	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clinical and Molecular Allergy, 2016, 14, 6.	0.8	37
187	Patients with antiphospholipid syndrome and thrombotic recurrences: A real world observation (the Tj ETQq1 1 0.784314 rgBT /Overlook	0.8	40
188	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology, 2016, 55, 1726-1735.	0.9	29
189	Emerging therapies in systemic lupus erythematosus: from clinical trial to the real life. Expert Review of Clinical Pharmacology, 2016, 9, 681-694.	1.3	4
190	New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. Autoimmunity Reviews, 2016, 15, 529-538.	2.5	64
191	Radiotherapy in patients with connective tissue diseases. Lancet Oncology, The, 2016, 17, e109-e117.	5.1	42
192	The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. American Journal of Obstetrics and Gynecology, 2016, 214, 273.e1-273.e8.	0.7	138
193	Antiphospholipid Antibodies and Syndrome: Complexities in Diagnosis and Management. , 2016, , 485-494.		0
194	Treatment of Antiphospholipid Syndrome. , 2016, , 543-549.		0
195	Immunogenetics of complement in mixed cryoglobulinaemia. Clinical and Experimental Rheumatology, 2016, 34, S12-5.	0.4	6
196	FRI0425â€¦The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 581.1-581.	0.5	0
197	Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 476-477.	0.5	49
198	Use of Intravenous Immunoglobulin in Patients With Active Vasculitis Associated With Concomitant Infection. Journal of Clinical Rheumatology, 2015, 21, 35-37.	0.5	5

#	ARTICLE	IF	CITATIONS
199	Thematic issue: Biologics in autoimmune diseases. <i>International Immunopharmacology</i> , 2015, 27, 179.	1.7	1
200	Upcoming biological therapies in systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2015, 27, 189-193.	1.7	14
201	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.	0.5	124
202	Biologics for the treatment of systemic lupus erythematosus: current status and emerging therapies. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 109-116.	1.3	41
203	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015, 14, 401-414.	2.5	194
204	Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?. <i>International Immunopharmacology</i> , 2015, 27, 220-223.	1.7	7
205	Rheumatoid arthritis: Biological therapy other than anti-TNF. <i>International Immunopharmacology</i> , 2015, 27, 185-188.	1.7	32
206	OPO188...Impact of Hydroxychloroquine Treatment on Pregnancy Outcome in Patients with Antiphospholipid Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 143.1-143.	0.5	0
207	A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment" Clinical response compared to literature and immunological re-assessment. <i>Autoimmunity Reviews</i> , 2015, 14, 1123-1130.	2.5	52
208	Antiphospholipid Syndrome and the Kidney. <i>Seminars in Nephrology</i> , 2015, 35, 478-486.	0.6	66
209	The global anti-phospholipid syndrome score in primary APS. <i>Rheumatology</i> , 2015, 54, 134-138.	0.9	87
210	Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: Case series and review of the literature. <i>Autoimmunity Reviews</i> , 2015, 14, 36-42.	2.5	22
211	Editorial paper Lupus and pregnancy in the 21st century. <i>Reumatologia</i> , 2014, 1, 1-3.	0.5	1
212	Thrombotic Risk Assessment in Systemic Lupus Erythematosus: Validation of the Global Antiphospholipid Syndrome Score in a Prospective Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1915-1920.	1.5	50
213	Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 354-364.	1.8	223
214	Targeted therapy in antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2014, 26, 269-275.	2.0	17
215	Renal involvement in antiphospholipid syndrome. <i>Nature Reviews Nephrology</i> , 2014, 10, 279-289.	4.1	84
216	Anticardiolipin Antibodies. , 2014, , 735-739.		0

#	ARTICLE	IF	CITATIONS
217	New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/PT) Antibodies. <i>Current Rheumatology Reports</i> , 2014, 16, 415.	2.1	30
218	Thrombotic risk assessment in APS: the Global APS Score (GAPSS). <i>Lupus</i> , 2014, 23, 1286-1287.	0.8	20
219	New Oral Anticoagulants in the Management of Venous Thromboembolism: A Major Advance?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2014, 48, 487-488.	0.8	2
220	Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. <i>Journal of Neurology</i> , 2014, 261, 1706-1714.	1.8	86
221	Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1309-1312.	0.8	18
222	Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. <i>Thrombosis Research</i> , 2014, 133, 451-454.	0.8	25
223	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	2.5	224
224	The Future Potential of Biosimilars Targeting B-Cells. <i>Milestones in Drug Therapy</i> , 2014, , 277-284.	0.1	0
225	Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 41-7.	0.4	20
226	Resolutive pulmonary endarterectomy in a non-compliant patient with systemic lupus erythematosus and antiphospholipid syndrome. <i>Rheumatology International</i> , 2013, 33, 1889-1893.	1.5	2
227	Is it time for biosimilars in autoimmune diseases?. <i>Autoimmunity Reviews</i> , 2013, 12, 954-957.	2.5	22
228	Management of infection in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 377-389.	1.4	34
229	The clinical relevance of IgA anticardiolipin and IgA anti- β 2 glycoprotein I antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2013, 12, 421-425.	2.5	69
230	The role of nail-videocapillaroscopy in early diagnosis of scleroderma. <i>Autoimmunity Reviews</i> , 2013, 12, 821-825.	2.5	44
231	Common variable immunodeficiency: Crossroads between infections, inflammation and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 796-801.	2.5	49
232	Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. <i>Autoimmunity Reviews</i> , 2013, 12, 426-429.	2.5	58
233	Long-term Follow-up of Young Adults With Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 321.	3.8	1
234	Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 142-143.	0.5	33

#	ARTICLE	IF	CITATIONS
235	GAPSS: the Global Anti-Phospholipid Syndrome Score. <i>Rheumatology</i> , 2013, 52, 1397-1403.	0.9	248
236	Antiphosphatidylserine/Prothrombin Antibodies in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 1620-1620.	1.0	0
237	OP0212...Very Long-Term Effects of the 4 Plus 2 Infusion Protocol of Rituximab Alone in Patients with HCV-Associated Mixed Cryoglobulinemia with Diffuse Membranoproliferative Glomerulonephritis, Severe Polyneuropathy and Necrotic Ulcers of Skin. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A124.1-A124.	0.5	0
238	Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. <i>Thrombosis and Haemostasis</i> , 2013, 109, 207-213.	1.8	58
239	High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 871.1-873.	1.0	2
240	Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. <i>Lupus</i> , 2012, 21, 806-809.	0.8	32
241	Systemic lupus erythematosus and infections: Clinical importance of conventional and upcoming biomarkers. <i>Autoimmunity Reviews</i> , 2012, 12, 157-163.	2.5	63
242	Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 273-277.	1.4	34
243	Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2512-2518.	1.9	96
244	Catastrophic antiphospholipid syndrome (CAPS). <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 535-541.	1.4	44
245	The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). <i>Thrombosis Research</i> , 2012, 130, 914-918.	0.8	16
246	8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. <i>Inflammation Research</i> , 2012, 61, 809-816.	1.6	27
247	Health Literacy and Discharge Instruction Adherence. <i>Journal of General Internal Medicine</i> , 2012, 27, 273-273.	1.3	9
248	Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. <i>Journal of Nephrology</i> , 2012, 25, 198-203.	0.9	22
249	Medical Students' Attitudes About Mental Illness. <i>Psychiatric Services</i> , 2012, 63, 836.	1.1	2
250	Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 409-13.	0.4	31
251	Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3987-3992.	0.4	61
252	Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. <i>American Journal of Nephrology</i> , 2011, 34, 175-180.	1.4	35

#	ARTICLE	IF	CITATIONS
253	Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. <i>Lupus</i> , 2011, 20, 1106-1108.	0.8	33
254	Exhaled breath condensate nitrates, but not nitrites or FENO, relate to asthma control. <i>Respiratory Medicine</i> , 2011, 105, 1007-1013.	1.3	24
255	Medical Students Need Training to Approach Chronic Pain. <i>Pain Medicine</i> , 2011, 12, 1692-1692.	0.9	0
256	How to improve our ability to predict adverse events in major surgery of SLE patients?. <i>Autoimmunity Reviews</i> , 2011, 10, 525-526.	2.5	1
257	Antiphospholipid syndrome and relapsing polychondritis: an unusual association. <i>Lupus</i> , 2011, 20, 1336-1337.	0.8	7
258	Unexplained chronic cough and vitamin B-12 deficiency. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 542-548.	2.2	24
259	Interleukin 6 Blockade as Steroid-sparing Treatment for 2 Patients with Giant Cell Arteritis: Figure 1.. <i>Journal of Rheumatology</i> , 2011, 38, 2080-2081.	1.0	52
260	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1083-1086.	0.5	178
261	Risk Scale for the diagnosis of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1517-1518.	0.5	43
262	Chronic Buddâ€“Chiari Syndrome, Abdominal Varices, and Caput Medusae in 2 Patients With Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 302.	0.5	10
263	Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. <i>Clinical and Experimental Allergy</i> , 2010, 40, 1642-1647.	1.4	36
264	Increased oral nitric oxide in obstructive sleep apnoea. <i>Respiratory Medicine</i> , 2010, 104, 316-320.	1.3	31
265	Prioritisation of health research. <i>Lancet, The</i> , 2010, 376, 513-514.	6.3	0
266	Neonatal lupus in triplet pregnancy of a patient with undifferentiated connective tissue disease evolving to systemic lupus erythematosus. <i>Lupus</i> , 2009, 18, 368-371.	0.8	3
267	Osteonecrosis and Antiphospholipid Antibodies. <i>Internal Medicine</i> , 2009, 48, 737-738.	0.3	2
268	Exhaled Nitric Oxide and Nitric Oxide Synthase Expression in Hodgkin's Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 1027-1034.	1.0	9
269	Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0